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For severe aortoiliac occlusive disease, conventional approach is aortobifemoral bypass (ABF) grafting in low-risk patients. [1] The early patency of ABF for critical limb ischemia is up to 100% and decreases to 87% at five years. [1] It is associated with major perioperative morbidity and mortality. [1] Extraanatomical bypasses are performed for high-risk patients who are in danger of limb loss. However, they are associated with limited patency. In patients with complete occlusion of the ipsilateral common and external iliac arteries and with contralateral iliac disease, stenting of the contralateral iliac artery with a crossover femoral-to-femoral artery bypass is an alternative to surgical ABF. [2] These hybrid procedures have been increasingly performed with good results. [2] They are also effective, as they need minimal surgical dissection and exposure and with less physiological disturbance, although their durability is still under observation. There are scanty data regarding the long-term patency of these procedures, particularly in developing countries. Herein, we present three cases of ipsilateral iliac stenting and femorofemoral crossover bypass (FFB) for critical limb ischemia with their long-term follow-up results.
CASE REPORT
All patients presented with critical limb ischemia. The details of patients are given in Table 1 . All patients underwent unilateral iliac stenting in radiology suite followed by FFB in the operation theater. The latter was performed under general anesthesia. Standard groin dissection was done to expose the femoral arteries. An externally supported polytetraf luoroethylene (PTFE) graft (6 or 8 mm in size) was used as the conduit. The graft was placed into the suprapubic subcutaneous space. In all patients, FFB was performed immediate after stenting on the same day. Restoration of the circulation was confirmed with palpable distal pulses at the end of the procedure. Postoperatively, all patients had smooth recovery. During a mean followup of four years, all patients had patent grafts with asymptomatic limbs. At discharge, at six months, and ©2019 Turkish National Vascular and Endovascular Surgery Society. All rights reserved.
annually thereafter, all patients had ankle-brachial index measurements.
DISCUSSION
The ABF grafting has remained the mainstay of treatment for symptomatic aortoiliac occlusive disease, being both durable and effective. [3] The patency rate of ABF is about 85 to 90% at five years. [4] However, it is an extensive surgical procedure with a high rate of associated complications (4 to 20%) and a mortality rate of 3 to 5%. [3] Hybrid procedures have emerged as a method of revascularization in patients with critical lower extremity ischemia having multilevel arterial occlusive disease.
In the literature, for unilateral iliac disease, FFB has both good short and long results; [5] however, in practice, iliac disease is usually more extensive rather than focal, involving both the iliac orifices in most of cases. It may compromises the patency of FFB. Earlier reports showed significant donor iliac stenosis as a risk for subsequent FFB failure. [6] The advent of endovascular techniques for the treatment of arterial occlusive disease has expanded the anatomical profile of patients deemed suitable to undergo FFB. Patients with donor inf low disease are anatomically eligible for a concomitant endovascular intervention at the time of surgery. Despite this evolution in practice, the reports of outcomes of FFB with an ipsilateral intervention remain somewhat limited. Previous reports have shown mixed results using donor iliac intervention in conjunction with FFB for patients with bilateral aortoiliac occlusive disease. Lopez-Galarza et al. [7] documented the associated five-year primary patency as 51% in a review of 18 patients who underwent FFB grafting with adjunctive iliac stenting in the setting of stenosis shorter than 3 cm. [7] Aburahma et al. [6] reported a series of 41 patients who underwent FFB, in whom 92% underwent iliac stenting in the setting of iliac lesions >5 cm in length, compared to with 14% who underwent associated stenting in the setting of a lesion <5 cm in length. For the durability of crossover grafting, it is important to handle contralateral iliac disease. There are series showing that selected iliac artery stenting has also improved the outcome of crossover bypass in patients with a suboptimal donor iliac artery. [8] Similar results were duplicated in our case patients. Furthermore, conduit for FFB is always a concern in terms of its long-term results. We used the PTFE as conduit in all patients. We believe using native venous grafts may add more operative time and can be at the cost of associated wound morbidity.
In conclusion, early and long-term results are encouraging with donor iliac stenting with FFB bypass in patients with symptomatic severe bilateral iliac disease.
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